

Medsafe consultation submission

Addition of warning statements on labels of OTC oral and topical diclofenac medicines				
Name and designation				
Company/organisation name and address				
Contact phone number and email address				
I would like the comments I have specific sections of response if a (Reasons for requesting confide	applicable)		dentify ☐ Yes ☐ No	
I would like my name to be removed from all documents prior to publication on the Medsafe website.			ebsite. Yes No	
I would like for my name not to be included within the list of submissions published on the Medsafe website.			Isafe Yes No	
It would help in the analysis of stakeholder comments if you provide the information requested below.				
I am, or I represent, an organisation that is based in:				
☐ New Zealand ☐ Australia ☐ Other (please specify):				
I am, or I represent, a: (tick	all that apply)			
☐ Importer	☐ Manufacturer	Supplier	☐ Sponsor	
Government	Researcher	☐ Professional body	☐ Industry organisation	
☐ Consumer organisation	☐ Member of the public	☐ Institution (e.g. unive	ersity, hospital)	
☐ Regulatory affairs consultant	☐ Laboratory professiona	al		
☐ Health professional – please	indicate type of practice:			
Other - please specify:				

Please return this form to:

Email: askmedsafe@moh.govt.nz including 'Diclofenac warning statements' in the subject line

Or Post: Product Regulation

Medsafe PO Box 5013 Wellington 6145

Medsafe is seeking comments on: Oral Diclofenac warning statements - Are the warning statements appropriate? - Are there other warning statements that should be added? Topical Diclofenac warning statements: - Are the warning statements appropriate? - Are there other warning statements that should be added?

Please include additional pages if necessary.

Medsafe consultation: Diclofenac warning statements

12 December 2015 - target date for implementation:		
- Is the target date for implementation in New Zealand reasonable, considering that this is also a target date in Australia?		